首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1735678

2026-2032 年獸醫自體疫苗市場：按菌株類型、最終用戶和地區分類

Veterinary Autogenous Vaccines Market By Strain Type (Bacterial, Virus), End-User (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes), And Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

獸醫自體疫苗市場評估-2026-2032

對客製化動物保健解決方案的需求不斷成長，推動了獸醫自體疫苗市場的發展。據 Verified Market Research 分析師稱，獸醫自體疫苗市場預計在 2024 年價值約為 1.3188 億美元，預計在預測期內將達到 2.0239 億美元的估值。

對疾病爆發的日益擔憂將推動獸醫自體疫苗市場的成長，該市場在 2026 年至 2032 年期間的複合年成長率將達到 5.5%。

自體動物疫苗的市場定義/概述

動物自體疫苗，也稱為自身疫苗或自體疫苗，是專門為預防特定地區或農場動物的疾病而量身訂做的疫苗。與大量生產用於一般用途的商業疫苗不同，自體疫苗旨在針對特定動物群體的感染疾病。這些疫苗的製備方法是從當地感染的動物體內分離病原體，在受控環境中進行培養，然後針對已識別的感染疾病生產疫苗。

此外，當商業疫苗無法有效或無法有效應對地方性或正在發展的病毒株時，通常會使用自體疫苗接種。自體疫苗常用於牲畜、水產養殖和伴侶動物保健機構，以應對局部疾病爆發，或針對某些動物族群通用疾病進行有針對性的預防。

影響獸醫自體疫苗市場成長的促進因素有哪些？

在全球範圍內，動物感染疾病的增加是自體疫苗需求成長的主要驅動力。隨著感染疾病的變異和新病毒株的出現，市售疫苗並不總是有效。針對特定動物群體感染的病原體菌株量身定做的自體疫苗，為疾病的控制和預防提供了更有針對性的方案。

標準疫苗並非對所有病原體菌株都有效，尤其是在應對新物種或位特異性突變時。當特定疾病無法透過常規疫苗提供保護時，自我免疫至關重要。這在集約化農業經營中尤其重要，因為疾病的傳播可能造成毀滅性後果。

此外，許多地區都制定了法律規範，允許在特定條件下使用自體疫苗，而無需獲得完整的上市核准。這種靈活性使獸醫和動物衛生專業人員能夠快速應對疾病爆發。一些國家的監管機構也認知到自體疫苗在動物健康管理中的重要性，並建議和支持其研究和使用。

獸用自體疫苗市場面臨的主要挑戰是什麼？

畜牧農民和寵物飼主對於自身疫苗接種的好處和可用性缺乏了解。這種缺乏了解，加上對這些疫苗接種的成本和實驗性質的擔憂，導致他們不願意採用自身疫苗接種而不是更標準的疫苗，從而阻礙了市場成長。

此外，自體疫苗的生產比常規疫苗更困難、更耗時；必須從每隻動物體內分離病原體，進行培養，並針對具體情況研發疫苗。這種方法不僅需要專門的設備和經驗，而且通常產量有限，並根據個體需求進行客製化。將此類疫苗快速運送到所需地點、在運輸過程中保持其效力，並確保抵達後正確儲存和處理，在物流方面可能面臨巨大限制，尤其是在偏遠和服務匱乏的地區。

概述
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 其他亞太地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中東和非洲
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲地區

第8章全球獸用自體疫苗市場競爭格局

概述
各公司市場排名
主要進展
公司地理分佈
公司產業足跡
ACE矩陣

第9章公司簡介

Boehringer Ingelheim International GmbH
Zoetis Inc.
Gallant Custom Laboratories
Ceva Biovac

第9.8章 SWOT分析

UVAXX
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利條件
- 當前重點和策略
- 競爭威脅
- SWOT分析
Delta動物保健
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利的關鍵
- 當前重點和策略
- 競爭威脅
- SWOT分析
熱那亞研究所
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利的關鍵
- 當前重點和策略
- 競爭威脅
- SWOT分析
High Gear生物實驗室
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利條件
- 當前重點和策略
- 競爭威脅
- SWOT分析
瓦奇諾娃
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利條件
- 當前重點和策略
- 競爭威脅
- SWOT分析
禮來動物保健
- 公司簡介
- 企業洞察
- 產品基準
- 主要進展
- 勝利的關鍵
- 當前重點和策略
- 競爭威脅
- SWOT分析

第10章已驗證的市場情報

關於已驗證的市場情報
動態資料視覺化

簡介目錄

Product Code: 35799

Veterinary Autogenous Vaccines Market Valuation - 2026-2032

Growing need for customized animal healthcare solutions propels the Veterinary Autogenous Vaccines Market forward. According to the analyst from Verified Market Research, the Veterinary Autogenous Vaccines Market is estimated to reach a valuation of USD 202.39 Million over the forecast subjugating around USD 131.88 Million valued in 2024.

Rising worries about disease outbreaks drive the growth of the Veterinary Autogenous Vaccines Market. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Veterinary Autogenous Vaccines Market: Definition/Overview

Veterinary autogenous vaccines, also known as autogenous or autologous vaccines, are custom-made vaccines designed to prevent diseases that affect animals in a specific geographic region or farm. Unlike commercial vaccinations, which are mass-produced for general usage, autogenous vaccines are designed to target infections that are peculiar to a particular animal group. These vaccines are created by isolating pathogens from diseased animals on-site, culturing them under controlled settings, and then manufacturing vaccinations that target the identified infections.

Furthermore, autogenous vaccinations are used largely when commercially available vaccines are inefficient or unavailable to address endemic diseases or developing strains. They are frequently employed in cattle farming, aquaculture, and companion animal healthcare settings to combat localized disease outbreaks or to give targeted protection against diseases common in a certain animal group.

What are the Drivers Influencing the Growth of the Veterinary Autogenous Vaccines Market?

The rising occurrence of numerous infectious diseases in animals around the world is a major driver of demand for autogenous vaccines. As infections mutate and new strains emerge, commercial vaccinations may not always be effective. Autogenous vaccinations, which are customized to the individual pathogen strains infecting a given animal population, provide a more targeted approach to disease management and prevention.

Standard vaccines not be effective against all strains of a pathogen, particularly when dealing with novel or region-specific variations. The uniqueness of autogenous vaccinations makes them essential in instances where ordinary vaccines fail to provide protection. This is especially important in intensive farming operations, where disease spread can have disastrous consequences.

Furthermore, many regions have a regulatory framework that allows veterinary autogenous vaccines to be used under certain conditions without requiring full marketing authorization. This flexibility allows veterinarians and animal health specialists to respond quickly to disease outbreaks with tailored remedies. Also, regulatory agencies in several countries have acknowledged the significance of autogenous vaccines in animal health management, giving recommendations and assistance for their research and usage.

What are the Main Challenges Faced by the Veterinary Autogenous Vaccines Market?

There is a shortage of knowledge among livestock farmers and pet owners regarding the benefits and availability of autogenous vaccinations. This lack of understanding, combined with worries about the expense and perceived experimental character of these vaccinations, resulted in reticence to embrace them over more standard vaccines, impeding market growth.

Furthermore, autogenous vaccines are more difficult and time-consuming to manufacture than regular vaccines. It entails isolating pathogens from the individual animals involved, growing them, and then developing a vaccine that is unique to the scenario. This method not only necessitates specialized equipment and experience, but it also implies that production volume is limited and frequently tailored to individual requests. The logistical constraints of providing these vaccines quickly to where they are required, preserving their efficacy during travel, and ensuring correct storage and handling upon arrival can be enormous, particularly in distant or underserved locations.

Category-wise Acumens

What Factors Contribute to the Increasing Demand for Bacterial Strain Vaccine Segment?

According to VMR analyst, the bacterial strain vaccine segment is expected to dominate the segment within the Veterinary Autogenous Vaccines Market during the forecast period. Bacterial infections in animals are common and can cause a wide range of illnesses, including respiratory and gastrointestinal problems, as well as skin and systemic infections. The diversity and prevalence of bacterial infections in livestock and companion animals necessitate the creation and application of bacterial autogenous vaccines. These vaccinations are critical in instances where commercial vaccines are ineffective against specific strains or varieties of bacteria that have arisen within a given herd or geographic area.

Bacteria have rapid mutation rates, which allows them to evolve swiftly and, in some cases, develop antibiotic resistance. This resistance complicates the management of bacterial illnesses, making immunization a more significant technique. Autogenous vaccines, which are tailored to specific strains of bacteria that pose a threat to a herd or group of animals, provide a targeted way to address antimicrobial resistance challenges.

Furthermore, bacterial autogenous vaccines can be produced more easily than viral vaccinations because bacteria may be grown in a variety of growth mediums. This flexibility enables quick vaccine development and distribution in response to epidemics. The specificity of bacterial autogenous vaccines ensures that they are effective against the specific strains causing disease in an animal population, giving them a significant advantage over broad-spectrum commercial vaccinations, which may not cover all strains.

What Factors Contribute to the Dominance of Veterinary Clinics in the Market?

The veterinary clinics segment is estimated to hold the largest share of the Veterinary Autogenous Vaccines Market during the forecast period. Veterinary clinics are the primary healthcare providers for animals, delivering a wide range of treatments from routine check-ups to emergency care. This close and regular connection with animals puts veterinary clinics in a unique position to discover specific health conditions that may necessitate the use of autogenous vaccinations. They can respond promptly to disease outbreaks within a certain herd or area by enabling the creation and distribution of these personalized vaccines.

Veterinary clinics are well positioned to benefit from autogenous vaccinations because of their intimate interaction with both animals and their owners. They have a complete health history and specialized knowledge of illness incidence in their area, which allows them to detect when commercial vaccines are insufficient and tailored remedies are required. This capacity to provide bespoke vaccine solutions broadens their service offering, catering to clients looking for the most effective disease prevention tactics for their animals.

Furthermore, unlike larger institutions or research facilities, veterinary clinics have the freedom to make swift judgments about the health management techniques they apply, such as the use of autogenous vaccinations. They can quickly work with autogenous vaccine makers to meet a pressing requirement, ensuring a prompt response to disease outbreaks. This agility improves their ability to safeguard animal health and limit disease transmission, which contributes greatly to their market dominance for these vaccines.

Country/Region-wise Acumens

How will the Demand for Veterinary Autogenous Vaccines Impact the Asia Pacific region?

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The region has experienced multiple high-profile animal disease outbreaks, including African Swine Fever (ASF) and Avian Influenza. These outbreaks highlight the limitations of traditional vaccinations and the need for more targeted vaccination regimens that can target specific disease strains. Autogenous vaccinations, which are tailored to the diseases afflicting a specific herd or flock, provide a viable answer to this problem, boosting their use.

Furthermore, the livestock sector in Asia Pacific is rapidly expanding, owing to rising demand for animal protein among the region's growing population. Countries such as China, India, and Southeast Asia are seeing fast expansion in the poultry, swine, and cattle industries. This development needs improved disease management tactics to safeguard animal health and productivity, driving demand for personalized vaccine solutions such as autogenous vaccines, especially in intensive agricultural operations where disease outbreaks are more likely.

Which Factors Contributes to the Market Dominance in North America?

North America is estimated to dominate the Veterinary Autogenous Vaccines Market during the forecast period. North America, particularly the United States and Canada, has a well-developed veterinary healthcare infrastructure. This comprises a huge number of veterinary clinics and hospitals with superior diagnosis and treatment capabilities, as well as a robust network of veterinary research institutions. The complex veterinary healthcare system promotes the research, approval, and use of new therapies and vaccines, including autogenous vaccinations, to meet the region's distinct animal population demands.

Furthermore, the region has a strong livestock industry and a high percentage of companion animal ownership, which drives the demand for veterinary services, particularly immunization. The necessity to protect these animals from disease outbreaks, particularly in dense farming operations or regions where animals come into close contact with one another, emphasizes the importance of customized medicine approaches such as autogenous vaccinations. These vaccinations are especially useful in managing disease outbreaks that cannot be efficiently managed with conventional immunizations.

Competitive Landscape

The Veterinary Autogenous Vaccines Market is highly competitive, with competitors ranging from small-scale local manufacturers to major global enterprises. Also, market participants are eager to improve their production capacity and invest in innovative manufacturing technologies to ensure vaccine scalability and efficiency.

Some of the prominent players operating in the Veterinary Autogenous Vaccines Market include:

Boehringer Ingelheim International GmbH, Zoetis Inc., Gallant Custom Laboratories, Ceva Biovac, Dyntec sro, UVAXX Pte Ltd, Deltamune Animal Health, Genova Labs, Hygieia Biological Laboratories, Vaxxinova, Elanco Animal Health, Addison Biological Laboratory, Phibro Animal Health Corporation, Lohmann Tierzucht, Aquatic Biologicals, Ridgeway Biologicals.

Latest Developments:

In February 2023, Gallant Custom Laboratories announced a collaboration with a technology company to create an automated system for autogenous vaccine manufacturing. This could increase efficiency and accessibility.

1 INTRODUCTION OF GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET

1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources

3 EXECUTIVE SUMMARY

3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Veterinary Autogenous Vaccines Market Geographical Analysis (CAGR %)
3.6 Global Veterinary Autogenous Vaccines Market, By Strain Type (USD Million)
3.7 Global Veterinary Autogenous Vaccines Market, By End-User (USD Million)
3.8 Future Market Opportunities
3.9 Global Market Split
3.10 Product Life Line

4 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET OUTLOOK

4.1 Global Veterinary Autogenous Vaccines Evolution
4.2 Drivers
- 4.2.1 Driver1
- 4.2.2 Driver 2
4.3 Restraints
- 4.3.1 Restraint1
- 4.3.2 Restraint 2
4.4 Opportunities
- 4.4.1 Opportunity1
- 4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis

5 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY SRAIN TYPE

5.1 Overview
5.2 Bacterial Strain
5.3 Virus Strain

6 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY END-USER

6.1 Overview
6.2 Veterinary Hospitals
6.3 Veterinary Clinics
6.4 Veterinary Research Institutes
6.5 Others

7 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Argentina
- 7.5.3 Rest of Latin America
7.6 Middle-East and Africa
- 7.6.1 UAE
- 7.6.2 Saudi Arabia
- 7.6.3 South Africa
- 7.6.4 Rest of Middle-East and Africa

8 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Developments
8.4 Company Regional Footprint
8.5 Company Industry Footprint
8.6 ACE Matrix

9 COMPANY PROFILES

9.1 Boehringer Ingelheim International GmbH
- 9.1.1 Company Overview
- 9.1.2 Company Insights
- 9.1.3 Product Benchmarking
- 9.1.4 Key Development
- 9.1.5 Winning Imperatives
- 9.1.6 Current Focus & Strategies
- 9.1.7 Threat from Competition
- 9.1.8 SWOT Analysis
9.2 Zoetis Inc.
- 9.2.1 Company Overview
- 9.2.2 Company Insights
- 9.2.3 Product Benchmarking
- 9.2.4 Key Development
- 9.2.5 Winning Imperatives
- 9.2.6 Current Focus & Strategies
- 9.2.7 Threat from Competition
- 9.2.8 SWOT Analysis
9.3 Gallant Custom Laboratories
- 9.3.1 Company Overview
- 9.3.2 Company Insights
- 9.3.3 Product Benchmarking
- 9.3.4 Key Development
- 9.3.5 Winning Imperatives
- 9.3.6 Current Focus & Strategies
- 9.3.7 Threat from Competition
- 9.3.8 SWOT Analysis
9.4 Ceva Biovac
- 9.4.1 Company Overview
- 9.4.2 Company Insights
- 9.4.3 Product Benchmarking
- 9.4.4 Key Development
- 9.4.5 Winning Imperatives
- 9.4.6 Current Focus & Strategies
- 9.4.7 Threat from Competition

9..8 SWOT Analysis

9.5 UVAXX Pte Ltd
- 9.5.1 Company Overview
- 9.5.2 Company Insights
- 9.5.3 Product Benchmarking
- 9.5.4 Key Development
- 9.5.5 Winning Imperatives
- 9.5.6 Current Focus & Strategies
- 9.5.7 Threat from Competition
- 9.5.8 SWOT Analysis
9.6 Deltamune Animal Health
- 9.6.1 Company Overview
- 9.6.2 Company Insights
- 9.6.3 Product Benchmarking
- 9.6.4 Key Development
- 9.6.5 Winning Imperatives
- 9.6.6 Current Focus & Strategies
- 9.6.7 Threat from Competition
- 9.6.8 SWOT Analysis
9.7 Genova Labs
- 9.7.1 Company Overview
- 9.7.2 Company Insights
- 9.7.3 Product Benchmarking
- 9.7.4 Key Development
- 9.7.5 Winning Imperatives
- 9.7.6 Current Focus & Strategies
- 9.7.7 Threat from Competition
- 9.7.8 SWOT Analysis
9.8 Hygieia Biological Laboratories
- 9.8.1 Company Overview
- 9.8.2 Company Insights
- 9.8.3 Product Benchmarking
- 9.8.4 Key Development
- 9.8.5 Winning Imperatives
- 9.8.6 Current Focus & Strategies
- 9.8.7 Threat from Competition
- 9.8.8 SWOT Analysis
9.9 Vaxxinova
- 9.9.1 Company Overview
- 9.9.2 Company Insights
- 9.9.3 Product Benchmarking
- 9.9.4 Key Development
- 9.9.5 Winning Imperatives
- 9.9.6 Current Focus & Strategies
- 9.9.7 Threat from Competition
- 9.9.8 SWOT Analysis
9.10 Elanco Animal Health
- 9.10.1 Company Overview
- 9.10.2 Company Insights
- 9.10.3 Product Benchmarking
- 9.10.4 Key Development
- 9.10.5 Winning Imperatives
- 9.10.6 Current Focus & Strategies
- 9.10.7 Threat from Competition
- 9.10.8 SWOT Analysis